https://www.syncsci.com/journal/CCR/issue/feed Current Cancer Reports 2025-05-13T16:25:31+08:00 April Chow april.chow@syncsci.com Open Journal Systems <p><a title="Registered Journal" href="https://www.reviewercredits.com/user/curr-cancer-rep" target="_blank" rel="noopener"><img class="journalreviewercredits" src="/journal/public/site/images/jasongong/Logo_ReviewerCredits-journal.jpg" alt="ReviewerCredits" align="right"></a><strong><em>Current Cancer Reports</em> (CCR)</strong> (eISSN: 2661-3166) is an open access, continuously published, international, refereed journal dedicated to publish articles covering all areas of carcinogenesis, prevention, diagnosis, treatment, drug development and related policy.</p> <p>The journal aims at promoting research communications, and providing a platform for doctors, researchers, physicians, pharmacists and healthcare professionals to find the most recent advances in all areas of cancer-related fields. Current Cancer Reports accepts original research articles, reviews, minireviews, case reports, image data, novel hypothesis and rapid communication covering all respects of carcinogenesis and cancer therapy.</p> <p>The columns of the journal include, but not limited to: <br>• Original articles and new techniques in cancer research and therapy<br>• Quick reports <br>• Case reports <br>• Clinicopathologic discussion <br>• Discussion of clinical case <br>• Expert views <br>• Exchange of experience <br>• Novel hypothesis <br>• Correspondence <br>• Publish the original incoming letter <br>• Academic contending/Debate <br>• etc.</p> https://www.syncsci.com/journal/CCR/article/view/CCR.2025.01.002 Optimizing Pre-operative Clinical Staging in Resectable Non-Small Cell Lung Cancer: A Retrospective Cohort Study 2025-05-13T16:25:31+08:00 Evangeline Samuel evangeline.samuel@monash.edu C. Thomas editor@syncsci.com C. Thompson editor@syncsci.com E. Paul editor@syncsci.com M. Cherk editor@syncsci.com S. Ellis editor@syncsci.com M. Siemienowicz editor@syncsci.com S. Tissera editor@syncsci.com U. Samankula editor@syncsci.com S. Scholz editor@syncsci.com L. Zhang editor@syncsci.com J. Grewal editor@syncsci.com J. Cox editor@syncsci.com C. Yu editor@syncsci.com G. Adabi editor@syncsci.com D. Keating editor@syncsci.com J. Taverner editor@syncsci.com J. Gooi editor@syncsci.com S. Wayne editor@syncsci.com John Zalcberg editor@syncsci.com Rob G. Stirling editor@syncsci.com <p><strong>Background:</strong> Accurate pre-operative clinical staging is vital for guiding treatment decisions in resectable non-small cell lung cancer (NSCLC). Discrepancies between clinical and pathological stages raise concerns about treatment appropriateness. <br><strong>Objective:</strong> The objective of the study is to determine the accuracy of the pre-operative clinical stage (cTN) with the post-operative pathological stage (pTN), examine factors predictive of inaccurate staging and explore the impacts on survival. <br><strong>Patient and Methods:</strong> This retrospective cohort study in Melbourne, Australia, analyzed stage I-IIIA NSCLC patients between 2011-2020. Primary exposures were pre-operative clinical stage (CT, PET, nodal evaluation) and post-operative pathological stage. The primary outcome was stage concordance between clinical and pathological stages of resected NSCLC. Various patient, tumour and surgical characteristics and quality of care metrics were collected from medical records. Logistic regression and COX proportional hazards regression assessed factors influencing staging concordance and survival. <br><strong>Results:</strong> Among 221 patients, 58% showed overall staging concordance. Discordance (42%) frequently led to upstaging (23.9%) or downstaging (17.2%) at pathology. Nodal stage concordance was influenced by female sex, SUV max, histology, and timing between CT and surgery. Nodal stage discordance independently correlated with higher mortality risk (p = 0.002, HR 2.37). <br><strong>Conclusions:</strong> The results of our study indicate inconsistencies between clinical methods of staging and pathological stages of NSCLC. Further optimization of clinical staging is essential for patients to receive guideline-concordant treatment. Pathological upstaging provides a significant safety risk and can result in adverse survival outcomes.</p> 2025-05-13T16:05:20+08:00 Copyright (c) 2025 Evangeline Samuel, C. Thomas, C. Thompson, E. Paul, M. Cherk, S. Ellis, M. Siemienowicz, S. Tissera, U. Samankula, S. Scholz, L. Zhang, J. Grewal, J. Cox, C. Yu, G. Adabi, D. Keating, J. Taverner, J. Gooi, S. Wayne, John Zalcberg, Rob G. Stirling https://www.syncsci.com/journal/CCR/article/view/CCR.2025.01.001 Association between Ribosomal Protein Gene Dysregulation and Tumor Biodiversity of Hepatocellular Carcinoma 2025-04-15T22:31:13+08:00 Zhimin Lu 1524818622@qq.com Sicong Xu 708902023@qq.com Guofeng Zhao zhaoguofeng527@163.com Ziyi Niu 18033763192@163.com Guoxin Hou gxhou91@163.com <p><strong>Background:</strong> Tumor cells are characterized by a higher production of ribosomes, which are necessary for maintaining enhanced cell growth and subsequent cell division. <br><strong>Aim:</strong> The study aimed to develop a prognostic ‌RPL score‌ for hepatocellular carcinoma (HCC) and explore its association with immune evasion mechanisms mediated by tumor microenvironment alterations.<br><strong>Methods:</strong> Using single-sample gene set enrichment analysis (ssGSEA), an RPLscore was constructed to estimate the dysregulation of ribosomal protein large (RPL) genes. The expression of RPL genes and their association with clinical outcomes and the tumor microenvironment (TME) were systematically investigated using bulk-seq and single-cell RNA-seq (scRNA-seq). <br><strong>Results:</strong> High expression levels of RPL in HCC were associated with poorer overall survival (OS) (P &lt; 0.001). The RPL score evaluated the RPL gene and verified its independent prognostic value for both OS and relapse-free survival (P = 0.0074 and P &lt; 0.001, respectively). TME analysis indicated that RPL gene dysregulation was closely associated with T cell exhaustion, myeloid-derived suppressor cell (MDSC) infiltration, and vascular dysplasia may be promoted by arginine deficiency (P = 7.6 × 10<sup>-10</sup>). The scRNA-seq data suggested that the RPL score was positively and significantly associated with the tumor biodiversity score (ITH score). <br><strong>Conclusion:</strong> The study highlights the prognostic value of the RPL score and its potential role in mediating immune evasion of HCC, which may provide an impetus for the development of new targets for the treatment of HCC.</p> 2025-04-15T15:43:47+08:00 Copyright (c) 2025 Zhimin Lu, Sicong Xu, Guofeng Zhao, Ziyi Niu, Guoxin Hou https://www.syncsci.com/journal/CCR/article/view/CCR.2024.01.006 Skin toxicities related to targeted therapy and immunotherapy for non-small cell lung cancer 2025-03-20T15:40:56+08:00 Jia Yan breakdurance@163.com Min Zhang 2735842893@qq.com <p>&nbsp;Non-small cell lung cancer (NSCLC) is the most common cancer, causing death and disability. Targeted therapy and immunotherapy have had an increasing role in the management of patients with advanced NSCLC. These treatments can produce an excellent curative effect, but the side effects should not be ignored. Skin toxicities such as papulopustular eruption, severe desquamation, and paronychia have a high incidence, seriously affecting patients’ quality of life and even interrupting treatment. Early recognition and adequate management are critical to prevent exacerbation of the lesions. This review describes the common skin toxicities related to targeted therapy and immunotherapy for NSCLC, summarizes the updated research progress of the mechanism, and proposes appropriate treatment and counseling for optimized management.</p> 2025-03-20T15:40:56+08:00 Copyright (c) 2025 Jia Yan, Min Zhang https://www.syncsci.com/journal/CCR/article/view/CCR.2024.01.005 Considering the clarithromycin resistance prevalence among Helicobacter pylori strains isolated from patients with Gastric complication 2025-03-19T08:53:09+08:00 Alireza Ahmadzadeh a.ahmadzadeh@sbmu.ac.ir Zhaleh Mohsenifar mohsenifar@sbmu.ac.ir Behzad Hatami bzd_hatami@yahoo.com Ali Pirsalehi pirsalehi@sbmu.ac.ir Mostafa Rezaei-Tavirani tavirany@yahoo.com <p><strong>Objective:</strong>&nbsp; <em>Helicobacter pylori</em> is a major cause of gastric cancer. This study aimed to determine the frequency of clarithromycin resistance and its association with point mutations in the 23S rRNA gene. <br><strong>Methods:</strong> This study was conducted on 100 patients with gastric disorders who were referred to Valiasr Hospital in 2022. Two biopsy samples were obtained from each patient for pathological and microbiological examinations. Antimicrobial susceptibility testing was performed using the agar dilution method, and polymerase chain reaction (PCR) was used for molecular analysis.<br><strong>Results:</strong> Among the patients, 53% (53/100) were diagnosed as <em>H. pylori</em>-positive. Pathological findings indicated that 54.7% (29/53) of the <em>H. pylori</em>-positive patients had chronic gastritis, 37.7% (20/53) had severe active gastritis, and 7.5% (4/53) had intestinal metaplasia. Clarithromycin resistance was detected in 13.2% (7/53) of the patients. The MIC50 and MIC90 values were determined to be 0.125 mg/L and 2 mg/L, respectively. PCR results revealed that the A2142G point mutation in the 23S rRNA gene was present in all clarithromycin-resistant strains. <br><strong>Conclusions:</strong> Our findings indicate that the presence of the A2142G point mutation in the 23S rRNA gene may be associated with clarithromycin resistance in <em>H. pylori</em> strains. These results underscore the importance of routine screening for resistance genotypes to guide effective treatment strategies.</p> 2025-03-17T12:22:52+08:00 Copyright (c) 2025 Alireza Ahmadzadeh, Zhaleh Mohsenifar, Behzad Hatami, Ali Pirsalehi, Mostafa Rezaei-Tavirani https://www.syncsci.com/journal/CCR/article/view/CCR.2024.01.004 A Knowledge-Based Planning model for IMRT in breast and lung cancer 2024-10-30T09:01:23+08:00 K. Keshav Kumar keshav.jntuh@gmail.com N. V. S. L. Narasimham nvsl.narasimham@gnits.ac.in A. Ramakrishna Prasad prof.prasadark@gmail.com <p><strong>Objective:</strong> The advent of Knowledge-Based Planning (KBP) models has introduced a transformative approach to Intensity-Modulated Radiation Therapy (IMRT) treatment planning in breast cancer and lung cancer cases. This paper explores the application of KBP models to these specific cancer types, highlighting their potential to enhance treatment accuracy, efficiency, and patient outcomes. <br><strong>Methods:</strong> By leveraging historical treatment data and machine learning techniques, KBP-IMRT offers a data-driven framework for optimizing dose distributions, minimizing radiation exposure to healthy tissues, and improving overall treatment plan quality. <br><strong>Results:</strong> Through a comprehensive review of the literature and clinical case studies, this paper underscores the advantages of KBP-IMRT, such as streamlined planning processes and improved plan consistency, while acknowledging the challenges associated with model development and implementation. <br><strong>Conclusion:</strong> As the field of radiotherapy continues to evolve, KBP models hold the promise of shaping the future of personalized and precise cancer treatment strategies.</p> 2024-10-29T12:10:52+08:00 Copyright (c) 2024 K. Keshav Kumar, N. V. S. L. Narasimham, A. Ramakrishna Prasad https://www.syncsci.com/journal/CCR/article/view/CCR.2024.01.003 Opportunities and challenges of multidisciplinary conversion therapy in advanced hepatocellular carcinoma 2024-09-12T10:59:03+08:00 Ju-Hang Chu editor@syncsci.com Lu-Yao Huang editor@syncsci.com Ya-Ru Wang editor@syncsci.com Jun Li editor@syncsci.com Ying-Yu Cui yycui@tongji.edu.cn Ming-Ping Qian editor@syncsci.com <p>Surgical resection is still the most important radical treatment for primary hepatocellular carcinoma (HCC), but at present, the resection rate of newly diagnosed patients with HCC is only 30%. The recurrence rate of newly diagnosed patients suitable for surgical resection within 5 years after surgery is as high as 40%~70%. Low initial resection rate and high postoperative recurrence rate are important reasons restricting the overall treatment effects of HCC in China. Under this background, effectively improving the resection rate of HCC and reducing the postoperative recurrence rate have become the key topics to improve the treatment effects of HCC. Some initially unresectable HCC patients may have access to surgery through conversion therapy. Conversion therapy, which mainly involves the combination of local, systemic, and multiple treatment strategies, offers hope for patients with advanced HCC. But there are still some patients who do not benefit from conversion therapy. So, how to improve the conversion success rate is still one of the challenges that clinicians need to solve.</p> 2024-09-11T10:16:44+08:00 Copyright (c) 2024 Ju-Hang Chu, Lu-Yao Huang, Ya-Ru Wang, Jun Li, Ying-Yu Cui, Ming-Ping Qian https://www.syncsci.com/journal/CCR/article/view/CCR.2024.01.002 Deep learning based capsule networks for breast cancer classification using ultrasound images 2024-08-27T14:24:34+08:00 Stephen Afrifa afrifastephen@tju.edu.cn Vijayakumar Varadarajan vijayakumar.varadarajan@gmail.com Tao Zhang zhangtao@tju.edu.cn Peter Appiahene peter.appiahene@uenr.edu.gh Daniel Gyamfi daniel.gyamfi@slu.edu Rose-Mary Owusuaa Mensah Gyening rmo.mensah@knust.edu.gh Jacob Mensah jacob.mensah@uenr.edu.gh Samuel Opoku Berchie soberchie@gmail.com <p><strong>Purposes</strong>: Breast cancer (BC) is a disease in which the breast cells multiply uncontrolled. Breast cancer is one of the most often diagnosed malignancies in women worldwide. Early identification of breast cancer is critical for limiting the impact on affected people's health conditions. The influence of technology and artificial intelligence approaches (AI) in the health industry is tremendous as technology advances. Deep learning (DL) techniques are used in this study to classify breast lumps. <br><strong>Materials and Methods</strong>: The study makes use of two distinct breast ultrasound images (BUSI) with binary and multiclass classification. To assist the models in understanding the data, the datasets are exposed to numerous preprocessing and hyperparameter approaches. With data imbalance being a key difficulty in health analysis, due to the likelihood of not having a condition exceeding that of having the disease, this study applies a cutoff stage to impact the decision threshold in the datasets data augmentation procedures. The capsule neural network (CapsNet), Gabor capsule network (GCN), and convolutional neural network (CNN) are the DL models used to train the various datasets.<br> <strong>Results</strong>: The findings showed that the CapsNet earned the maximum accuracy value of 93.62% while training the multiclass data, while the GCN achieved the highest model accuracy of 97.08% when training the binary data. The models were also evaluated using a variety of performance assessment parameters, which yielded consistent results across all datasets. <br><strong>Conclusion</strong>: The study provides a non-invasive approach to detect breast cancer; and enables stakeholders, medical practitioners, and health research enthusiasts a fresh view into the analysis of breast cancer detection with DL techniques to make educated judgements.</p> 2024-08-27T11:33:14+08:00 Copyright (c) 2024 Stephen Afrifa, Vijayakumar Varadarajan, Tao Zhang, Peter Appiahene, Daniel Gyamfi, Rose-Mary Owusuaa Mensah Gyening, Jacob Mensah, Samuel Opoku Berchie https://www.syncsci.com/journal/CCR/article/view/CCR.2024.01.001 Nanotherapeutics to cure inflammation-induced cancer 2024-07-02T14:20:38+08:00 Rajiv Kumar chemistry_rajiv@hotmail.com <p><strong>Aims: </strong>Nanotherapeutics are being explored as a potential solution to treat inflammation-induced cancer. Nanotherapeutics enhance innate immune cells' immunity, enabling them to fight tumors effectively. These cells secrete specific chemicals like cytokines, allowing them to replicate quickly and respond to future threats, making them suitable for immunotherapy.<br><strong>Methods: </strong>Nanotechnology can significantly improve human health by enhancing infection detection, prevention, and treatment. Nanomedicines, composed of restorative and imaging compounds in submicrometer-sized materials, aim to deliver effective treatments and limit inflammation in healthy body areas. Combining nanotechnology and clinical sciences, nanoparticles are suitable for gene therapy and have been developed for treating various diseases, including cancer, cardiovascular, diabetes, pulmonary, and inflammatory diseases.<br><strong>Results: </strong>Neutrophils and their offspring, including films and extracellular vehicles, are crucial drug transporters for enhanced growth therapy. Tumor microenvironment inputs can modify tumor-associated neutrophils (TANs), which are essential for tumor growth and healing. Human tumor intratumor heterogeneity is crucial for tumor growth and healing. Nanomedicines have shown potential in targeted delivery, toxicity reduction, and therapeutic effectiveness enhancement. However, clinical relevance and efficacy remain inadequate due to a lack of understanding of the interaction between nanomaterials, nanomedicine, and biology. The diverse biological milieu impacts the dynamic bioidentity of nanoformulations, and their interactions can modify therapeutic function or cellular absorption.<br><strong>Conclusion: </strong>Nanotechnology holds great promise for improving human health by detecting, preventing, and treating infections. Nanomedicines, a fusion of clinical sciences and nanotechnology, use submicrometer-sized transporter materials for therapy delivery and reducing contamination. Nanoparticles' small size and high surface-to-volume ratio can benefit gene therapy. Research has led to a wide range of nanomedicine products globally.</p> 2024-07-02T14:20:23+08:00 Copyright (c) 2024 Rajiv Kumar https://www.syncsci.com/journal/CCR/article/view/CCR.2023.01.006 Breast carcinoma in the Democratic Republic of the Congo: Characterization of hormone receptors 2024-03-26T16:52:58+08:00 Guy Ilunga Nday editor@syncsci.com Manix Banza Ilunga editor@syncsci.com Anasthasie Umpungu Ngalula editor@syncsci.com Olivier Mukuku oliviermukuku@yahoo.fr Jules Thaba Ngwe editor@syncsci.com <p><strong>Purpose</strong>: Breast cancer is a heterogeneous disease, and understanding its characteristics is crucial for effective treatment. Therefore, this study aims to investigate breast carcinomas as a function of hormone receptors (estrogen and progesterone) in the Democratic Republic of the Congo (DRC), which can contribute to better management of breast cancer cases in the country.<br><strong>Methods</strong><em>:</em> We conducted an analytical cross-sectional study from 2014 to 2016 in the cities of Kinshasa and Lubumbashi. Using non-random sampling, we collected 86 cases of breast carcinoma.<br><strong>Results</strong><em>:</em> The study found that out of the 86 cases of breast carcinoma, 33 patients (38.3%) had both types of hormone receptors (ER+/PgR+), while 37 patients (43.0%) had negative results for both receptor types (ER-/PgR-). Additionally, 15 patients (17.4%) had only estrogen receptors. The study did not find any significant association between the presence of estrogen receptors and patient age, T stage, histological type, and Ki67 proliferation index. However, the study did observe that estrogen receptors were significantly more present in grade I and II tumors (74.4%) than in grade III tumors (40.4%) (Odds ratio=4.3 [1.7-10.8]; p=0.003).<br><strong>Conclusion</strong>: The findings of this study demonstrate a high prevalence of hormone receptors in breast cancer cases in the DRC. Additionally, the study revealed a significant association between the presence of estrogen receptors and tumor grade, underlining the relevance of these markers in the characterization and treatment of the disease.</p> 2024-03-26T16:51:36+08:00 Copyright (c) 2024 Guy Ilunga Nday, Manix Banza Ilunga, Anasthasie Umpungu Ngalula, Olivier Mukuku, Jules Thaba Ngwe https://www.syncsci.com/journal/CCR/article/view/CCR.2023.01.005 Perspectives on chemotherapy-induced toxicities in pancreatic cancer 2025-01-23T16:39:44+08:00 Henu Kumar Verma henu.verma@yahoo.com Tarun Sahu editor@syncsci.com LVKS Bhaskar lvksbhaskar@gmail.com <p>Despite breakthroughs in screening, identification, and therapy, pancreatic cancer (PC) remains a serious issue in cancer-related mortality. This comprehensive review investigates the long-term and latent effects of chemotherapy in PC, focusing on commonly used medicines such as gemcitabine, docetaxel, irinotecan, nab-paclitaxel, and others. Gemcitabine, a common PC medication, causes a variety of adverse effects, including myelosuppression and weariness. Combination therapy, such as docetaxel and irinotecan, enhance toxicity, resulting in problems such as neutropenia and gastrointestinal difficulties. Significantly, chemotherapy-related complications, such as thrombosis and cardiac difficulties connected to paclitaxel, present serious concerns. Erlotinib, gefitinib, vatalanib, and sunitinib studies show significant side effects. Despite ongoing challenges, determining the causes of the low objective response rate in gemcitabine-refractory patients remains challenging. The study emphasizes the importance of future advances in cancer etiology, arguing for large, straightforward studies examining combination chemotherapies to improve tolerance and minimize chemotherapy-induced sequelae. This overview serves as a thorough guide for physicians, researchers, and policymakers as they navigate the complex terrain of PC chemotherapy, providing significant insights to improve patient care.</p> 2024-02-20T11:04:27+08:00 Copyright (c) 2024 Henu Kumar verma, Tarun Sahu, LVKS Bhaskar